Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "analogues" to "analogs") |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Melanoma]] | *[[Melanoma]] | ||
**[[Uveal melanoma]] | **[[Uveal melanoma]] | ||
| Line 19: | Line 19: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | ||
| Line 25: | Line 25: | ||
*1975-05-27: Initial FDA approval | *1975-05-27: Initial FDA approval | ||
*Uncertain date: indicated in the treatment of metastatic malignant [[melanoma]]. ''(No supporting studies are cited)'' | *Uncertain date: indicated in the treatment of metastatic malignant [[melanoma]]. ''(No supporting studies are cited)'' | ||
| − | *Uncertain date: Indicated for [[Hodgkin lymphoma|Hodgkin's disease]] as a second-line therapy when used in combination with other effective agents. ''(No supporting studies are cited)'' | + | *Uncertain date: Indicated for [[Classical Hodgkin lymphoma|Hodgkin's disease]] as a second-line therapy when used in combination with other effective agents. ''(No supporting studies are cited)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *1978-02-01: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2013-03-25: New additional indication and a new dosage for the treatment of [[pheochromocytoma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' dacarbazin, DTIC, imidazole carboxamide | *'''Generic names:''' dacarbazin, DTIC, imidazole carboxamide | ||
| Line 42: | Line 45: | ||
[[Category:Human DNA synthesis inhibitors]] | [[Category:Human DNA synthesis inhibitors]] | ||
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
| − | [[Category:Purine | + | [[Category:Purine analogs]] |
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Leiomyosarcoma medications]] | [[Category:Leiomyosarcoma medications]] | ||
| Line 55: | Line 58: | ||
[[Category:FDA approved in 1975]] | [[Category:FDA approved in 1975]] | ||
| + | [[Category:EMA approved in 1978]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 13:27, 23 September 2023
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1975-05-27: Initial FDA approval
- Uncertain date: indicated in the treatment of metastatic malignant melanoma. (No supporting studies are cited)
- Uncertain date: Indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents. (No supporting studies are cited)
History of changes in EMA indication
- 1978-02-01: EURD
History of changes in PMDA indication
- 2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.
Also known as
- Generic names: dacarbazin, DTIC, imidazole carboxamide
- Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Alkylating agents
- Triazenes
- Human DNA synthesis inhibitors
- Antimetabolites
- Purine analogs
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Leiomyosarcoma medications
- Liposarcoma medications
- Melanoma medications
- Neuroblastoma medications
- Pheochromocytoma medications
- Soft tissue sarcoma medications
- Uveal melanoma medications
- FDA approved in 1975
- EMA approved in 1978
- WHO Essential Cancer Medicine